Mesoblast (NASDAQ:MESO) Reaches New 12-Month High – Should You Buy?

Mesoblast Limited (NASDAQ:MESO) reached a new 52-week high during mid-day trading on Monday . The company traded as high as $12.25 and last traded at $12.16, with a volume of 90051 shares trading hands. The stock had previously closed at $11.76.

Analyst Upgrades and Downgrades

Several equities analysts have commented on the stock. Jefferies Financial Group raised shares of Mesoblast from a “hold” rating to a “buy” rating in a research report on Thursday, August 29th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Mesoblast in a research report on Thursday, August 29th. StockNews.com cut shares of Mesoblast from a “hold” rating to a “sell” rating in a research note on Wednesday, September 4th. Finally, Maxim Group upgraded shares of Mesoblast from a “hold” rating to a “buy” rating and set a $12.00 target price on the stock in a report on Tuesday, September 24th. One equities research analyst has rated the stock with a sell rating and four have given a buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $11.50.

Mesoblast Stock Up 2.9 %

The company has a current ratio of 1.18, a quick ratio of 1.18 and a debt-to-equity ratio of 0.21. The business’s fifty day moving average price is $10.08 and its 200 day moving average price is $8.08.

Institutional Investors Weigh In On Mesoblast

Large investors have recently modified their holdings of the stock. Signaturefd LLC boosted its stake in Mesoblast by 128.7% in the 3rd quarter. Signaturefd LLC now owns 5,506 shares of the company’s stock valued at $45,000 after buying an additional 3,099 shares in the last quarter. Pine Valley Investments Ltd Liability Co bought a new position in shares of Mesoblast during the second quarter valued at $80,000. Perkins Coie Trust Co boosted its stake in shares of Mesoblast by 15.0% in the 3rd quarter. Perkins Coie Trust Co now owns 11,500 shares of the company’s stock valued at $94,000 after purchasing an additional 1,500 shares in the last quarter. Rathbones Group PLC bought a new stake in shares of Mesoblast in the 2nd quarter worth about $95,000. Finally, XTX Topco Ltd acquired a new stake in shares of Mesoblast during the 2nd quarter worth about $103,000. 1.43% of the stock is currently owned by institutional investors.

About Mesoblast

Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells.